药物-药物共晶的研究进展

doi:10.11949/0438-1157.20201139

摘要/Abstract

摘要：

联合用药在临床治疗中显示出降低药物剂量、毒性、耐药性以及提高治疗效果的潜在优势。药物-药物共晶作为联合用药的一种新方法，在分子水平上实现了药物的联合，有望解决联合用药中存在的原料药之间的溶解度差异大、不相容和稳定性差等问题，近几年来引起了研究人员的广泛关注。本文综述了药物-药物共晶的概念和优势，药物-药物共晶的形成、溶解和代谢机理，以及药物-药物共晶的设计和预测方法，最后总结了药物-药物共晶领域尚需解决的问题，并对未来的发展方向进行了展望。

关键词: 药物-药物共晶, 形成机理, 溶解, 代谢, 设计, 预测

Abstract:

Combination drugs show the potential advantages of reducing drug dosage, toxicity, drug resistance and improving therapeutic effect in clinical treatment. As a new method of combined medicine, drug-drug co-crystals have achieved drug efficiency at the molecular level. It is expected to solve the problems of significant solubility difference, incompatibility and poor stability between drug ingredients. This paper reviews the concept and advantages of drug-drug co-crystals, the formation, dissolution and metabolism mechanisms of drug-drug co-crystals. How to design and predict drug-drug co-crystals from both theoretical and experimental aspects is introduced. Finally, the problems of drug-drug co-crystals that need to be solved are summarized, and the future development direction of drug-drug co-crystals is prospected.

Key words: drug-drug co-crystals, formation mechanism, dissolution, metabolism, design, prediction

中图分类号:

TQ 460.1

孙晶晶, 贾丽娜, 林波, 王艳, 龚俊波. 药物-药物共晶的研究进展[J]. 化工学报, 2021, 72(2): 828-840.

SUN Jingjing, JIA Lina, LIN Bo, WANG Yan, GONG Junbo. Research advances of drug-drug co-crystals[J]. CIESC Journal, 2021, 72(2): 828-840.

图/表 7

参考文献 89

1	Simon F. The trouble with making combination drugs [J]. Nature Reviews Drug Discovery, 2006, 5(11): 881-882.
2	Wang J, Yu Q, Dai W, et al. Drug-drug co-crystallization presents a new opportunity for the development of stable vitamins [J]. Chemical Communications, 2016, 52(17): 3572-3575.
3	Jiang L, Huang Y, Zhang Q, et al. Preparation and solid-state characterization of dapsone drug-drug co-crystals [J]. Crystal Growth & Design, 2014, 14(9): 4562-4573.
4	Online Computer Library Center. Reflection paper on the use of cocrystals of active substances in medicinal products [EB]. [2015-07-16]. .
5	Online Computer Library Center. Regulatory classification of pharmaceutical co-crystals guidance for industry [EB]. [2018-02-15]. .
6	Putra O D, Furuishi T, Yonemochi E, et al. Drug-drug multicomponent crystals as an effective technique to overcome weaknesses in parent drugs [J]. Crystal Growth & Design, 2016, 16(7): 3577-3581.
7	Vilar L, Canadas V, Arruda M J, et al. Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes[J]. Arquivos Brasileiros de Endocrinologia & Metabologia, 2010, 54(3): 311-318.
8	Jones G, Prosser D E, Kaufmann M. The activating enzymes of vitamin D metabolism (25-and 1α-hydroxylases)[M]//Vitamin D. New York: Academic Press, 2018: 57-79.
9	Swapna B, Maddileti D, Nangia A. Cocrystals of the tuberculosis drug isoniazid: polymorphism, isostructurality, and stability [J]. Crystal Growth & Design, 2014, 14(11): 5991-6005.
10	王灵宇, 杜世超, 董伟兵. 药物共晶多晶型的研究进展[J]. 化学工业与工程, 2018, 35(3): 29-37.
	Wang L Y, Du S C, Dong W B. Research advances of polymorphism in pharmaceutical cocrystals[J]. Chemical Industry and Engineering, 2018, 35(3): 29-37.
11	He H, Jiang L, Zhang Q, et al. Polymorphism observed in dapsone-flavone cocrystals that present pronounced differences in solubility and stability [J]. CrystEngComm, 2015, 17(34): 6566-6574.
12	Porter W W, Elie S C, Matzger A J. Polymorphism in carbamazepine cocrystals [J]. Crystal Growth & Design, 2008, 8(1): 14-16.
13	Sekhon B S. Drug-drug co-crystals [J]. DARU, 2012, 20(1): 45-45.
14	Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis [J]. The American Journal of Medicine, 2007, 120(8): 713-719.
15	Fox Z, Dragsted U B, Gerstoft J, et al. A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial [J]. Antiviral Therapy, 2006, 11(6): 761-770.
16	Mitsuya H, Yarchoan R, Broder S. Molecular targets for AIDS therapy [J]. Science, 1990, 249(4976): 1533-1544.
17	Bhatt P M, Azim Y, Thakur T S, et al. Co-crystals of the anti-HIV drugs Lamivudine and Zidovudine [J]. Crystal Growth & Design, 2009, 9(2): 951-957.
18	Putra O D, Yoshida T, Umeda D, et al. Crystal structure determination of dimenhydrinate after more than 60 years: solving salt-cocrystal ambiguity via solid-state characterizations and solubility study [J]. Crystal Growth & Design, 2016, 16(9): 5223-5229.
19	Nagashima K, Takahashi A, Ikeda H, et al. Sulfonylurea and non-sulfonylurea hypoglycemic agents: pharmachological properties and tissue selectivity[J]. Diabetes Research and Clinical Practice, 2004, 66: S75-S78.
20	Setter S M, Iltz J L, Thams J, et al. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy[J]. Clinical Therapeutics, 2003, 25(12): 2991-3026.
21	Jia L, Wu S, Gong J. A tolbutamide-metformin salt based on antidiabetic drug combinations: synthesis, crystal structure analysis and pharmaceutical properties [J]. Acta Crystallographica Section C-Crystal Structure Communications, 2019, 75(9): 1250-1258.
22	Kuroda R, Higashiguchi K, Hasebe S, et al. Crystal to crystal transformation in the solid state [J]. CrystEngComm, 2004, 6(76): 464-468.
23	Chadwick K, Davey R J, Cross W I. How does grinding produce co-crystals? Insights from the case of benzophenone and diphenylamine [J]. CrystEngComm, 2007, 9(9): 732-734.
24	Nguyen K L, Friscic T, Day G M, et al. Terahertz time-domain spectroscopy and the quantitative monitoring of mechanochemical cocrystal formation [J]. Nature Materials, 2007, 6(3): 206-209.
25	Jayasankar A, Somwangthanaroj A, Shao Z J, et al. Cocrystal formation during cogrinding and storage is mediated by amorphous phase [J]. Pharmaceutical Research, 2006, 23(10): 2381-2392.
26	Friscic T, Jones W. Recent advances in understanding the mechanism of cocrystal formation via grinding [J]. Crystal Growth & Design, 2009, 9(3): 1621-1637.
27	Seefeldt K, Miller J M, Alvareznunez F, et al. Crystallization pathways and kinetics of carbamazepine-nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy, and calorimetry studies [J]. Journal of Pharmaceutical Sciences, 2007, 96(5): 1147-1158.
28	Karki S, Friscic T, And W J, et al. Screening for pharmaceutical cocrystal hydrates via neat and liquid-assisted grinding [J]. Molecular Pharmaceutics, 2007, 4(3): 347-354.
29	Friscic T, Childs S L, Rizvi S A A, et al. The role of solvent in mechanochemical and sonochemical cocrystal formation: a solubility-based approach for predicting cocrystallisation outcome [J]. CrystEngComm, 2009, 11(3): 418-426.
30	Rehder S, Klukkert M, Lobmann K, et al. Investigation of the formation process of two piracetam cocrystals during grinding [J]. Pharmaceutics, 2011, 3(4): 706-722.
31	Friščić T, Trask A V, Jones W, et al. Screening for inclusion compounds and systematic construction of three‐component solids by liquid‐assisted grinding[J]. Angewandte Chemie, 2006, 45(45): 7546-7550.
32	Wang N, Hao H, Lu H, et al. Molecular recognition and self-assembly mechanism of cocrystallization processes [J]. CrystEngComm, 2017, 19(27): 3746-3752.
33	Sun S, Zhang H, Xu J, et al. The competition between cocrystallization and separated crystallization based on crystallization from solution [J]. Journal of Applied Crystallography, 2019, 52(4): 769-776.
34	Maheshwari C, André V, Reddy S, et al. Tailoring aqueous solubility of a highly soluble compound via cocrystallization: effect of coformer ionization, pHmax and solute-solvent interactions [J]. CrystEngComm, 2012, 14(14): 4801-4811.
35	Sathisaran I, Dalvi S V. Engineering cocrystals of poorly water-soluble drugs to enhance dissolution in aqueous medium [J]. Pharmaceutics, 2018, 10(3): 108.
36	Babu N J, Nangia A. Solubility advantage of amorphous drugs and pharmaceutical cocrystals [J]. Crystal Growth & Design, 2011, 11(7): 2662-2679.
37	Chieng N, Aaltonen J, Saville D J, et al. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation [J]. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 71(1): 47-54.
38	Friscic T, Jones W. Benefits of cocrystallisation in pharmaceutical materials science: an update [J]. Journal of Pharmacy and Pharmacology, 2010, 62(11): 1547-1559.
39	Mauritz J M A, Morrisby R S, Hutton R S, et al. Imaging pharmaceutical tablets with optical coherence tomography [J]. Journal of Pharmaceutical Sciences, 2010, 99(1): 385-391.
40	Bavishi D D, Borkhataria C H. Spring and parachute: how cocrystals enhance solubility [J]. Progress in Crystal Growth and Characterization of Materials, 2016, 62(3): 1-8.
41	Huang Y, Zhang B, Gao Y, et al. Baicalein-nicotinamide cocrystal with enhanced solubility, dissolution, and oral bioavailability [J]. Journal of Pharmaceutical Sciences, 2014, 103(8): 2330-2337.
42	McNamara D P, Childs S L, Giordano J, et al. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API [J]. Pharmaceutical Research, 2006, 23(8): 1888-1897.
43	Hickey M B, Peterson M L, Scoppettuolo L, et al. Performance comparison of a co-crystal of carbamazepine with marketed product [J]. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 67(1): 112-119.
44	Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs[J]. Expert Opinion on Drug Delivery, 2007, 4(4): 403-416.
45	Patel N, Gluck J. Is Entresto good for the brain?[J]. World Journal of Cardiology, 2017, 9(7): 594-599.
46	Emami S, Siahi-Shadbad M, Adibkia K, et al. Recent advances in improving oral drug bioavailability by cocrystals [J]. Bioimpacts, 2018, 8(4): 305-320.
47	Langenickel T H, Dole W P. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure[J]. Drug Discovery Today: Therapeutic Strategies, 2012, 9(4): e131-e139.
48	Haneef J, Chadha R. Drug-drug multicomponent solid forms: cocrystal, coamorphous and eutectic of three poorly soluble antihypertensive drugs using mechanochemical approach [J]. AAPS PharmSciTech, 2017, 18(6): 2279-2290.
49	Sarmah K K, Nath N, Rao D R, et al. Mechanochemical synthesis of drug-drug and drug-nutraceutical multicomponent solids of olanzapine [J]. CrystEngComm, 2020, 22(6): 1120-1130.
50	Thipparaboina R, Kumar D, Chavan R B, et al. Multidrug co-crystals: towards the development of effective therapeutic hybrids [J]. Drug Discovery Today, 2016, 21(3): 481-490.
51	Kumar S, Nanda A. Approaches to design of pharmaceutical cocrystals: a review [J]. Mol. Cryst. Liquid Cryst., 2018, 667(1): 54-77.
52	Miroshnyk I, Mirza S, Sandler N. Pharmaceutical co-crystals—an opportunity for drug product enhancement [J]. Expert Opinion on Drug Delivery, 2009, 6(4): 333-341.
53	Fleischman S G, Kuduva S S, Mcmahon J A, et al. Crystal engineering of the composition of pharmaceutical phases: multiple-component crystalline solids involving carbamazepine [J]. Crystal Growth & Design, 2003, 3(6): 909-919.
54	Aakeroy C B, Salmon D J. Building co-crystals with molecular sense and supramolecular sensibility [J]. CrystEngComm, 2005, 7(72): 439-448.
55	Braga D, Grepioni F. Making crystals from crystals: a green route to crystal engineering and polymorphism[J]. Chemical Communications, 2005, (29): 3635-3645.
56	Bis J A, Vishweshwar P, Weyna D, et al. Hierarchy of supramolecular synthons: persistent hydroxyl···pyridine hydrogen bonds in cocrystals that contain a cyano acceptor [J]. Molecular Pharmaceutics, 2007, 4(3): 401-416.
57	Thakuria R, Delori A, Jones W, et al. Pharmaceutical cocrystals and poorly soluble drugs [J]. International Journal of Pharmaceutics, 2013, 453(1): 101-125.
58	Maddileti D, Swapna B, Nangia A. High solubility crystalline pharmaceutical forms of blonanserin[J]. Crystal Growth & Design, 2014, 14(5): 2557-2570.
59	马坤. 药物的共晶与盐[J]. 中国药科大学学报, 2012, 43(5): 475-480.
	Ma K. Pharmaceutical cocrystals and salts[J]. Journal of China Pharmaceutical University, 2012, 43(5): 475-480.
60	Silva C C P D, Pepino R D O, de Melo C C, et al. Controlled synthesis of new 5-fluorocytosine cocrystals based on the pK_a rule [J]. Crystal Growth & Design, 2014, 14(9): 4383-4393.
61	Grecu T, Adams H, Hunter C A, et al. Virtual screening identifies new cocrystals of nalidixic acid [J]. Crystal Growth & Design, 2014, 14(4): 1749-1755.
62	Grecu T, Hunter C A, Gardiner E J, et al. Validation of a computational cocrystal prediction tool: comparison of virtual and experimental cocrystal screening results [J]. Crystal Growth & Design, 2014, 14(1): 165-171.
63	Grecu T, Prohens R, Mccabe J F, et al. Cocrystals of spironolactone and griseofulvin based on an in silico screening method [J]. CrystEngComm, 2017, 19(26): 3592-3599.
64	Wood P A, Feeder N, Furlow M, et al. Knowledge-based approaches to co-crystal design [J]. CrystEngComm, 2014, 16(26): 5839-5848.
65	Delori A, Galek P T A, Pidcock E, et al. Knowledge-based hydrogen bond prediction and the synthesis of salts and cocrystals of the anti-malarial drug pyrimethamine with various drug and GRAS molecules [J]. CrystEngComm, 2013, 15(15): 2916-2928.
66	Habgood M, Deij M A, Mazurek J, et al. Carbamazepine co-crystallization with pyridine carboxamides: rationalization by complementary phase diagrams and crystal energy landscapes [J]. Crystal Growth & Design, 2010, 10(2): 903-912.
67	Fabian L. Cambridge structural database analysis of molecular complementarity in cocrystals [J]. Crystal Growth & Design, 2009, 9(3): 1436-1443.
68	Issa N, Karamertzanis P G, Welch G W A, et al. Can the formation of pharmaceutical cocrystals be computationally predicted?(Ⅰ): Comparison of lattice energies [J]. Crystal Growth & Design, 2009, 9(1): 442-453.
69	Mohammad M, Alhalaweh A, Velaga S P. Hansen solubility parameter as a tool to predict cocrystal formation [J]. International Journal of Pharmaceutics, 2011, 407(1): 63-71.
70	Lu E, Rodríguez-Hornedo N, Suryanarayanan R. A rapid thermal method for cocrystal screening [J]. CrystEngComm, 2008, 10(6): 665-668.
71	Saganowska P, Wesolowski M. DSC as a screening tool for rapid co-crystal detection in binary mixtures of benzodiazepines with co-formers [J]. Journal of Thermal Analysis and Calorimetry, 2018, 133(1): 785-795.
72	Yamashita H, Hirakura Y, Yuda M, et al. Detection of cocrystal formation based on binary phase diagrams using thermal analysis [J]. Pharmaceutical Research, 2013, 30(1): 70-80.
73	Yamashita H, Hirakura Y, Yuda M, et al. Coformer screening using thermal analysis based on binary phase diagrams [J]. Pharmaceutical Research, 2014, 31(8): 1946-1957.
74	Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties [J]. Crystal Growth & Design, 2009, 9(6): 2950-2967.
75	Cherukuvada S, Nangia A. Eutectics as improved pharmaceutical materials: design, properties and characterization [J]. Chemical Communications, 2014, 50(8): 906-923.
76	Yan Y, Chen J, Lu T. Thermodynamics and preliminary pharmaceutical characterization of a melatonin-pimelic acid cocrystal prepared by a melt crystallization method [J]. CrystEngComm, 2015, 17(3): 612-620.
77	Sathisaran I, Dalvi S V. Crystal engineering of curcumin with salicylic acid and hydroxyquinol as coformers [J]. Crystal Growth & Design, 2017, 17(7): 3974-3988.
78	Skieneh J M, Sathisaran I, Dalvi S V, et al. Co-amorphous form of curcumin-folic acid dihydrate with increased dissolution rate [J]. Crystal Growth & Design, 2017, 17(12): 6273-6280.
79	Chow S F, Shi L, Ng W W, et al. Kinetic entrapment of a hidden curcumin cocrystal with phloroglucinol [J]. Crystal Growth & Design, 2014, 14(10): 5079-5089.
80	Malamatari M, Ross S A, Douroumis D, et al. Experimental cocrystal screening and solution based scale-up cocrystallization methods [J]. Advanced Drug Delivery Reviews, 2017, 117: 162-77.
81	Chiarella R A, Davey R J, Peterson M L. Making co-crystals: the utility of ternary phase diagrams [J]. Crystal Growth & Design, 2007, 7(7): 1223-1226.
82	Zhang S, Chen H, Rasmuson Å C. Thermodynamics and crystallization of a theophylline-salicylic acid cocrystal [J]. CrystEngComm, 2015, 17(22): 4125-4135.
83	Good D J, Rodríguez-Hornedo N. Cocrystal eutectic constants and prediction of solubility behavior [J]. Crystal Growth & Design, 2010, 10(3): 1028-1032.
84	Lange L, Lehmkemper K, Sadowski G. Predicting the aqueous solubility of pharmaceutical cocrystals as a function of pH and temperature [J]. Crystal Growth & Design, 2016, 16(5): 2726-2740.
85	Sun X, Yin Q, Ding S, et al. Solid-liquid phase equilibrium and ternary phase diagrams of ibuprofen-nicotinamide cocrystals in ethanol and ethanol/water mixtures at (298.15 and 313.15) K [J]. Journal of Chemical & Engineering Data, 2015, 60(4): 1166-1172.
86	Duggirala N K, Perry M L, Almarsson Ö, et al. Pharmaceutical cocrystals: along the path to improved medicines [J]. Chemical Communications, 2016, 52(4): 640-655.
87	Desai A S, McMurray J J V, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients [J]. European Heart Journal, 2015, 36(30): 1990-1997.
88	Videla S, Lahjou M, Vaqué A, et al. Single‐dose pharmacokinetics of co‐crystal of tramadol-celecoxib: results of a four‐way randomized open‐label phase I clinical trial in healthy subjects[J]. British Journal of Clinical Pharmacology, 2017, 83(12): 2718-2728.
89	Almansa C, Mercè R, Tesson N, et al. Co-crystal of tramadol hydrochloride-celecoxib (ctc): a novel API-API co-crystal for the treatment of pain [J]. Crystal Growth & Design, 2017, 17(4): 1884-1892.

[1]	胡超, 董玉明, 张伟, 张红玲, 周鹏, 徐红彬. 浓硫酸活化五氧化二钒制备高浓度全钒液流电池正极电解液[J]. 化工学报, 2023, 74(S1): 338-345.
[2]	陈哲文, 魏俊杰, 张玉明. 超临界水煤气化耦合SOFC发电系统集成及其能量转化机制[J]. 化工学报, 2023, 74(9): 3888-3902.
[3]	齐聪, 丁子, 余杰, 汤茂清, 梁林. 基于选择吸收纳米薄膜的太阳能温差发电特性研究[J]. 化工学报, 2023, 74(9): 3921-3930.
[4]	车睿敏, 郑文秋, 王小宇, 李鑫, 许凤. 基于离子液体的纤维素均相加工研究进展[J]. 化工学报, 2023, 74(9): 3615-3627.
[5]	杨百玉, 寇悦, 姜峻韬, 詹亚力, 王庆宏, 陈春茂. 炼化碱渣湿式氧化预处理过程DOM的化学转化特征[J]. 化工学报, 2023, 74(9): 3912-3920.
[6]	于旭东, 李琪, 陈念粗, 杜理, 任思颖, 曾英. 三元体系KCl + CaCl₂ + H₂O 298.2、323.2及348.2 K相平衡研究及计算[J]. 化工学报, 2023, 74(8): 3256-3265.
[7]	闫琳琦, 王振雷. 基于STA-BiLSTM-LightGBM组合模型的多步预测软测量建模[J]. 化工学报, 2023, 74(8): 3407-3418.
[8]	尹刚, 李伊惠, 何飞, 曹文琦, 王民, 颜非亚, 向禹, 卢剑, 罗斌, 卢润廷. 基于KPCA和SVM的铝电解槽漏槽事故预警方法[J]. 化工学报, 2023, 74(8): 3419-3428.
[9]	郑玉圆, 葛志伟, 韩翔宇, 王亮, 陈海生. 中高温钙基材料热化学储热的研究进展与展望[J]. 化工学报, 2023, 74(8): 3171-3192.
[10]	郭雨莹, 敬加强, 黄婉妮, 张平, 孙杰, 朱宇, 冯君炫, 陆洪江. 稠油管道水润滑减阻及压降预测模型修正[J]. 化工学报, 2023, 74(7): 2898-2907.
[11]	文兆伦, 李沛睿, 张忠林, 杜晓, 侯起旺, 刘叶刚, 郝晓刚, 官国清. 基于自热再生的隔壁塔深冷空分工艺设计及优化[J]. 化工学报, 2023, 74(7): 2988-2998.
[12]	李艳辉, 丁邵明, 白周央, 张一楠, 于智红, 邢利梅, 高鹏飞, 王永贞. 非常规服役超临界锅炉的微纳尺度腐蚀动力学模型建立及应用[J]. 化工学报, 2023, 74(6): 2436-2446.
[13]	于源, 陈薇薇, 付俊杰, 刘家祥, 焦志伟. 几何相似涡流空气分级机环形区流场变化规律研究及预测[J]. 化工学报, 2023, 74(6): 2363-2373.
[14]	江锦波, 彭新, 许文烜, 门日秀, 刘畅, 彭旭东. 泵出型螺旋槽油气密封泄漏特性及参数影响研究[J]. 化工学报, 2023, 74(6): 2538-2554.
[15]	陈科, 杜理, 曾英, 任思颖, 于旭东. 四元体系LiCl+MgCl₂+CaCl₂+H₂O 323.2 K相平衡研究及计算[J]. 化工学报, 2023, 74(5): 1896-1903.